Amneal Reconciled Depreciation from 2010 to 2024

AMRX Stock  USD 8.27  0.08  0.96%   
Amneal Pharmaceuticals, Reconciled Depreciation yearly trend continues to be fairly stable with very little volatility. Reconciled Depreciation will likely drop to about 208.8 M in 2024. During the period from 2010 to 2024, Amneal Pharmaceuticals, Reconciled Depreciation regression line of annual values had r-squared of  0.78 and arithmetic mean of  123,955,183. View All Fundamentals
 
Reconciled Depreciation  
First Reported
2017-09-30
Previous Quarter
55.5 M
Current Value
55.6 M
Quarterly Volatility
14.6 M
 
Covid
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 154.9 M, Interest Expense of 119.8 M or Selling General Administrative of 281.2 M, as well as many indicators such as Price To Sales Ratio of 0.42, Dividend Yield of 0.096 or PTB Ratio of 56.75. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
  
Check out the analysis of Amneal Pharmaceuticals, Correlation against competitors.

Latest Amneal Pharmaceuticals,'s Reconciled Depreciation Growth Pattern

Below is the plot of the Reconciled Depreciation of Amneal Pharmaceuticals, Class over the last few years. It is Amneal Pharmaceuticals,'s Reconciled Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
Reconciled Depreciation10 Years Trend
Slightly volatile
   Reconciled Depreciation   
       Timeline  

Amneal Reconciled Depreciation Regression Statistics

Arithmetic Mean123,955,183
Geometric Mean93,361,268
Coefficient Of Variation72.17
Mean Deviation83,220,462
Median45,936,000
Standard Deviation89,458,239
Sample Variance8002.8T
Range194.2M
R-Value0.88
Mean Square Error1901.7T
R-Squared0.78
Significance0.000013
Slope17,659,147
Total Sum of Squares112038.9T

Amneal Reconciled Depreciation History

2024208.8 M
2023229.4 M
2022240.2 M
2021233.4 M
2020235.4 M
2019207.2 M
2018137.4 M

About Amneal Pharmaceuticals, Financial Statements

Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Reconciled Depreciation, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Reconciled Depreciation229.4 M208.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.